cytostatic agent
Enable an AI agent to recognise a cytostatic agent, assess evidence that it inhibits cell proliferation, and identify the conditions and constraints governing its handling and use.
Bundle → Layer → Finding → Questions Filled
6 bundles · 11 layers · 18 findings · 28 questions
Identity and classification Establishes which substances this functional class includes and on what evidence.
Class boundary
Defines the intended meaning of cytostatic agent and its neighbouring classes.
Cytostatic membership
Record the working definition and the evidence required to classify a substance under it.
- Does this registry entry cover any substance with demonstrated cytostatic activity or a narrower medicinal class? definition
- What evidence distinguishes membership here from cytotoxic-agent or antineoplastic-agent classification? boundary
Active substance resolution
Connects class membership to the material actually studied.
Tested material identity
Record whether activity belongs to a specified compound, chemical form, mixture, or biologically generated active species.
- Which identified substance and chemical form were present in the reported experiment? provenance
- Was activity attributed to the supplied substance, an active metabolite, or an unresolved component? boundary
Mechanism and cellular context Relates proliferation inhibition to cellular processes and biological dependencies.
Mechanistic support
Separates observed inhibition from proposed causal explanations.
Target-to-arrest evidence
Record evidence connecting target engagement or pathway modulation to reduced cell division.
- Which experiments connect the proposed molecular action to proliferation inhibition? provenance
- What cell-cycle distribution or division-tracking result supports the proposed arrest mechanism? measurement
Response dependencies
Captures the cellular features and conditions associated with activity.
Responsive cell context
Record tested populations, their proliferative state, and supported sensitivity or resistance factors.
- Which cell populations and baseline proliferative states were tested? provenance
- Which molecular or environmental features were demonstrated to alter the response? measurement
Exposure and effect evidence Defines how cytostatic activity was measured and how it changes with exposure.
Proliferation measurement
Makes activity measurements interpretable and comparable.
Growth inhibition endpoint
Record the assay endpoint, baseline, controls, exposure conditions, and uncertainty supporting an inhibition claim.
- What endpoint measures proliferation, and how is it normalised to baseline and controls? measurement
- What concentrations, exposure durations, replicates, and uncertainty estimates accompany the result? measurement
Effect persistence
Tracks proliferation during exposure and after withdrawal.
Withdrawal and regrowth
Record recovery observations without assuming all cytostatic effects are reversible.
- Does proliferation resume after withdrawal, and over what observation interval? measurement
- What evidence distinguishes persistent arrest from residual exposure or delayed cell death? boundary
Cytotoxicity and selectivity Separates inhibited division from cell loss and qualifies claims of selective activity.
Viability discrimination
Pairs proliferation evidence with measurements of survival or death.
Arrest versus cell loss
Record whether the observed response reflects arrest, death, or a mixture at each relevant exposure.
- Which independent viability or death measurements accompany the proliferation endpoint? measurement
- Under which tested conditions does the response shift between predominantly cytostatic and predominantly cytotoxic? boundary
Comparative selectivity
Limits selectivity claims to the populations and conditions actually compared.
Selectivity comparator
Record comparative effects on intended target populations and relevant non-target populations.
- Which target and non-target populations were compared under matched exposure conditions? provenance
- How were differences in baseline division rate addressed when interpreting apparent selectivity? measurement
Preparation and controlled handling Connects biological interpretation and permissible actions to the actual preparation and its documented hazards.
Exposure material quality
Records preparation properties that influence delivered concentration and activity.
Preparation integrity
Track solvent, concentration, storage history, and evidence of stability or incompatibility relevant to the intended context.
- What preparation and stability evidence supports the stated concentration during use? provenance
- Which observed or documented conditions require the preparation to be withheld, replaced, or reassessed? action
Handling and disposition
Associates manipulation and waste actions with applicable documented requirements.
Substance-specific controls
Record relevant exposure routes, containment, spill response, and waste instructions for the identified preparation.
- Which current safety data sheet and local assessment govern this substance and preparation? provenance
- What controls and authorised procedures apply to preparation, transfer, spills, and disposal? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of cytostatic agent this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these kinds and varieties hold for the sense of cytostatic agent this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these identifiers and schemes hold for the sense of cytostatic agent this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of cytostatic agent this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these typical measurements hold for the sense of cytostatic agent this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of cytostatic agent this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these regional variation hold for the sense of cytostatic agent this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of cytostatic agent this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Physical world and living systems
- Entry kind
- thing
- Plane
- PHY
- Domain
- PHY.OBJ
- Other names and narrower kinds
- platinum-based antineoplastic
What it is Filled
A cytostatic agent is a substance that inhibits cell proliferation by slowing or arresting cell-cycle progression, without necessarily killing the affected cells.
In scope
- Substance identity and evidence supporting classification as a cytostatic agent
- Mechanism and cellular context of proliferation inhibition
- Concentration, exposure duration, and reversibility of observed effects
- Selectivity and distinction between proliferation inhibition and cell death
- Preparation, stability, containment, and disposal requirements
Out of scope
- Patient-specific treatment selection, prescribing, and dosing
- Cancer and other disease models
- Complete treatment regimens and interactions among their components
- Manufacturing facilities and administration devices
- Cell-culture and assay protocols as independently managed procedures
- Commercial medicinal products and individual stock containers as separate entities
Why it exists Filled
Enable an AI agent to recognise a cytostatic agent, assess evidence that it inhibits cell proliferation, and identify the conditions and constraints governing its handling and use.
Distinguishing features Filled
- Classification requires evidence of inhibited cell proliferation in a stated biological and exposure context; a therapeutic label alone is insufficient.
- A claim of cytostatic activity must distinguish reduced proliferation from loss of viable cells rather than infer arrest solely from a lower cell count.
- Cytostatic and cytotoxic effects must be recordable together when their balance changes with concentration, exposure duration, or cell population.
- The entry represents a functional class of substances, while named compounds, marketed formulations, and individual samples require separate identities.
- Anticancer use, cell-cycle target engagement, or an antimicrobial effect alone does not establish the particular cytostatic activity being claimed.
What robots and AI may and may not do Filled
Must not
- Recommend, dose or adjust a cytostatic agent for a particular patient.
- Handle or dispose of these drugs outside the site's hazardous drug procedures.
- Promote unproven substances as cytostatic cancer cures.
- Disclose a person's cancer treatment without consent.
Only with a human decision
- Any prescribing or treatment decision.
- Responding to a spill of a hazardous drug.
May
- Explain what cytostatic agents are and how they differ from cytotoxic drugs, from reliable sources.
- Report safe handling requirements from official guidance and product labelling.
- Track stock and handling records in a pharmacy the agent is authorized to manage.
Moral aspects Filled
- Cancer patients need accurate information and protection from false cures.
- Health workers who handle these drugs can be harmed by repeated exposure.
Who is affected
- Patients
- Nurses and pharmacists
- Families and carers
Owners Filled
Steward
The prescribing clinician for each use; medicines regulators authorize products.
Master systems
- National medicines registers
Links to other meta-models Filled
parent
- Q12140 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.cytostatic-agent
- Wikidata: Q2140638 (https://www.wikidata.org/wiki/Q2140638)
Direct properties required Filled
- Substance identity: Links to identified active substances, chemical forms, and authoritative identity records
- Classification basis: Observed proliferation inhibition; reported class membership; unresolved
- Biological test context: Cell population, species, tissue origin, culture or organism context, and relevant molecular features
- Exposure concentration: mol/L or mass/volume, with chemical form and nominal or measured status
- Exposure duration: Hours or days, including continuous, pulsed, and washout intervals
- Proliferation response: Assay-defined growth rate, division count, or percentage inhibition relative to a specified control
- Concurrent viability response: Viable-cell fraction or death-associated endpoint, with method and observation time
- Recovery after withdrawal: Proliferation resumes; inhibition persists over observation period; mixed response; untested
- Mechanistic attribution: Supported links to molecular targets, pathways, and cell-cycle effects
- Preparation suitability: Meets specified preparation criteria; degraded; precipitated; contaminated; expired under applicable specification; unknown
- Handling classification: Applicable safety data sheet, hazard assessment, containment requirements, and waste rules
Recognition not applicable Not applicable
Not applicable
Cytostatic activity is a biological effect that cannot be established from a substance's appearance or dosage form.
Capabilities and actions required Filled
- Assess whether a substance qualifies as cytostatic within a documented biological context.
- Compare proliferation responses when exposure conditions, controls, and endpoints are sufficiently aligned.
- Identify evidence needed to distinguish growth inhibition from cell death.
- Trace a claimed mechanism to supporting experiments and record competing explanations.
- Check a preparation against substance-specific stability and handling requirements.
- Route proposed use, transfer, or disposal through the applicable protocol and responsible authority.
Hazards and failure modes required Filled
- Can suppress the immune system and harm a developing fetus.
- Occupational exposure needs protective handling.
Standards and interfaces required Filled
- Directive 2001/83/EC, adopted by the European Parliament and the Council of the European Union, establishes the Community code relating to medicinal products for human use and applies to cytostatic medicines within its scope.
- The Federal Food, Drug, and Cosmetic Act, enacted by the United States Congress, governs human drugs including cytostatic medicines marketed in the United States.
Context of use required Filled
- Cytostatic drugs are encountered in clinical treatment and biomedical research where inhibition of cell proliferation is an intended effect.
- The term describes a biological effect across different substances, so interpretation depends on the particular drug, target cells and evidence.
Sources Filled
- Wikidata item Q2140638: cytostatic agent - identity and sense of the item
- Wikipedia: Cytostatic agent - general description of the item
Open questions
- Does the registry intend a broad functional class of proliferation-inhibiting substances or the narrower usage found in particular medicinal classifications?
- Does an existing Vercy world model already own this concept, requiring the registry entry to link to it?
- Which authoritative sources should establish the working definition and resolve overlap with cytotoxic and antineoplastic terminology?
- What minimum combination of proliferation, viability, and recovery evidence should support a cytostatic classification?
- How should evidence for metabolites, mixtures, and formulations be linked without incorrectly transferring activity to every associated substance?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q2140638/spec.json